Form 10-K

IntelGenx Enters into Feasibility & Development Agreement For CBD-Infused VetaFilm™

Retrieved on: 
Wednesday, November 9, 2022
GLOBE, Feasibility study, Risk, Annual report, CBD, Development, Securities Act of 1933, R, IP, U.S. Securities and Exchange Commission, Securities Exchange Act of 1934, Form 10-K, IGX, Patient, Physician, CEO, TSX, Drug Quality and Security Act, Animal, Agreement, Pharmaceutical industry, Medical device

Pursuant to the Agreement, IntelGenx will provide a CBD-infused VetaFilm product prototype for clinical investigation.

Key Points: 
  • Pursuant to the Agreement, IntelGenx will provide a CBD-infused VetaFilm product prototype for clinical investigation.
  • Based on successful feasibility, IntelGenx will enter into negotiations for a commercial agreement, pursuant to which IntelGenx will have exclusive rights to further develop, manufacture and supply the developed product.
  • This agreement marks yet another important first for us within the animal health space, said Dr. Horst G. Zerbe, CEO of IntelGenx.
  • IntelGenx is a leading drug delivery company focused on the development and manufacturing of pharmaceutical films.

Molson Coors Beverage Company Announces Regular Quarterly Dividend

Retrieved on: 
Thursday, November 10, 2022
Retail, Restaurant, Bar, Food, Beverage, Wine & Spirits, People, Director, Molson Brewery, Maharajkumar of Vizianagram, NYSE, Molson Coors Beverage Company, Republic of Ireland, Drink, Environment, Blue moon, Board, MCBC, Form, EMEA, Bangladesh Securities and Exchange Commission, U.S. Securities and Exchange Commission, Form 10-K, MCCI, Social, TSX, Coors Brewing Company, Biophysical environment, APAC, Coors Light, Beer, Board of directors, Holding company, Carling Brewery

The quarterly dividend is payable to holders of Class A and Class B common stock of Molson Coors Beverage Company.

Key Points: 
  • The quarterly dividend is payable to holders of Class A and Class B common stock of Molson Coors Beverage Company.
  • In addition, the Board of Directors of Molson Coors Canada Inc. (TSX: TPX.B, TPX.A) today declared a quarterly dividend of approximately CDN$0.50 (the Canadian dollar equivalent of the dividend declared on Molson Coors Beverage Company stock), payable December 15, 2022, to its Class A and Class B exchangeable shareholders of record on December 2, 2022.
  • For more than two centuries Molson Coors Beverage Company has been brewing beverages that unite people for all lifes moments.
  • About Molson Coors Canada Inc.
    Molson Coors Canada Inc. (MCCI) is a subsidiary of Molson Coors Beverage Company.

Boston Omaha Corporation Announces Third Quarter 2022 Financial Results

Retrieved on: 
Thursday, November 10, 2022
Professional Services, Advertising, Communications, Technology, Insurance, Telecommunications, Finance, Investment, U.S. Securities and Exchange Commission, Form 10-Q, Advertising, Private Securities Litigation Reform Act, Class, SEC, Telecommunication, Company, Form 10-K, Security (finance), Insurance, History, COVID-19, Internet service provider

Our book value per share was $16.83 at September 30, 2022, compared to $16.71 at December 31, 2021.

Key Points: 
  • Our book value per share was $16.83 at September 30, 2022, compared to $16.71 at December 31, 2021.
  • As of September 30, 2022, we had 28,642,801 shares of Class A common stock and 1,055,560 shares of Class B common stock issued and outstanding.
  • As of November 9, 2022, we had 28,642,801 shares of Class A common stock and 1,055,560 shares of Class B common stock issued and outstanding.
  • Boston Omaha Corporation is a public holding company with four majority owned businesses engaged in outdoor advertising, surety insurance, broadband telecommunications services and asset management.

InfuSystem to Participate at 13th Annual Craig-Hallum Alpha Select Conference on November 17, 2022

Retrieved on: 
Thursday, November 10, 2022
General Health, Health, Medical Supplies, Medical Devices, ITS, Forward-looking statement, NYSE, Form 10-Q, Risk, Annual report, COVID-19, Securities Act of 1933, Share repurchase, Excellent, Securities Exchange Act of 1934, Sheraton New York Times Square Hotel, Contract, Company, Form 10-K, Conference, Employee Retirement Income Security Act of 1974, Pain management, Lymphedema, Risk management

The conference will be held at the Sheraton New York Times Square in New York City.

Key Points: 
  • The conference will be held at the Sheraton New York Times Square in New York City.
  • Investors interested in arranging one-on-one meetings should contact your Craig-Hallum conference representative.
  • Conversely, you may also call or email Lytham Partners at 602-889-9700, or [email protected] .
  • InfuSystem Holdings, Inc. (NYSE American: INFU), is a leading national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers.

Rallybio Announces Proposed Public Offering

Retrieved on: 
Thursday, November 10, 2022
Professional Services, Health, Consumer, Baby, Maternity, Finance, General Health, Biotechnology, Attention, J.P. Morgan & Co., U.S. Securities and Exchange Commission, Telephone, Research, Annual report, Sale, Form S-3, Prospectus, Hematology, SEC, Form, Equity capital markets, Company, Form 10-K, Corporation, University, Degenerative disease, Patient, Security (finance), LLC

Rallybio Corporation (Rallybio) (Nasdaq: RLYB) today announced the commencement of a proposed public offering of $75 million of its shares of common stock (and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock).

Key Points: 
  • Rallybio Corporation (Rallybio) (Nasdaq: RLYB) today announced the commencement of a proposed public offering of $75 million of its shares of common stock (and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock).
  • The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
  • J.P. Morgan, Cowen and Evercore ISI are acting as joint lead book-running managers for the proposed offering.
  • Applicable risks and uncertainties include those related to market conditions and satisfaction of customary closing conditions related to the proposed public offering.

Trio-Tech Reports First Quarter Net Income of $0.21 Per Share As Revenue Increased 17%

Retrieved on: 
Thursday, November 10, 2022
Technology, Networks, Hardware, Semiconductor, Private Securities Litigation Reform Act, Devaluation, Exchange, NYSE, U.S. Securities and Exchange Commission, Risk, Novation Companies, Technology, Securities Act of 1933, International, Securities Exchange Act of 1934, Company, Form 10-K, NYSE MKT, Terminology, CEO, Security (finance), Industry, COVID-19, Income, Bank

Revenue for the three months ended September 30, 2022 increased 17% to $11,939,000 compared to $10,171,000 for the three months ended September 30, 2021, highlighted by a 38% increase in testing services revenue.

Key Points: 
  • Revenue for the three months ended September 30, 2022 increased 17% to $11,939,000 compared to $10,171,000 for the three months ended September 30, 2021, highlighted by a 38% increase in testing services revenue.
  • Overall gross margin increased 14%, but declined to 30% of revenue compared to 31% of revenue in the same quarter last year, primarily related to lower margin product mix at testing services and manufacturing operations.
  • Net income for the first quarter of fiscal 2023 was $882,000, or $0.21 per diluted share, compared to net income of $917,000, or $0.23 per diluted share, for the first quarter last year.
  • Shareholders' equity at September 30, 2022 decreased to $27,818,000, or $6.82 per outstanding share, compared to $28,002,000, or $6.88 per outstanding share at June 30, 2022.

Biodesix Presents New Data from the INSIGHT Study at the 2022 Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting

Retrieved on: 
Thursday, November 10, 2022
Research, Clinical Trials, Health Technology, Biotechnology, Health, General Health, Other Science, Science, Oncology, Triage, Private Securities Litigation Reform Act, Diagnosis, Forward-looking statement, University, Risk, Degenerative disease, Intelligence, Annual general meeting, Immunotherapy, Nasdaq, Malignancy, Annual report, Lung cancer, Population, Classification, ICI, Society for Immunotherapy of Cancer, Large-cell lung carcinoma, Artificial intelligence, Patient, Survival, SITC, INSIGHT, Company, Form 10-K, Journal, Poster, JITC, Validation, Biotechnology, Medicare, Veristrat, NSCLC, Physician, Society, MD, Blood, COVID-19, Vaccine, Pharmaceutical industry, Cancer

The poster, titled Host Immune Profiling in First-line Immunotherapy Treated Advanced Stage Non-Small Cell Lung Cancer: Results from the INSIGHT Registry Study, will be presented on Friday, November 11th, 2022.

Key Points: 
  • The poster, titled Host Immune Profiling in First-line Immunotherapy Treated Advanced Stage Non-Small Cell Lung Cancer: Results from the INSIGHT Registry Study, will be presented on Friday, November 11th, 2022.
  • HIC-C classification, also known as VeriStrat Poor, correlates to what experts refer to as an immune desert, where tumor directed immunity is compromised.
  • The new data expands the analysis population to a total of 3,040 patients and confirms the ability of the VeriStrat test to predict outcomes in patients treated with immunotherapy regimens.
  • This new data from the INSIGHT study shows how a biomarker-driven strategy can help determine optimal treatment approaches for these patients.

Logility Positioned as a Leader in Four IDC MarketScape Assessments on Supply Chain Planning

Retrieved on: 
Thursday, November 10, 2022
Technology, Transport, Professional Services, Software, Data Analytics, Data Management, Logistics, Supply Chain Management, Supply Chain Management, Retail, Artificial Intelligence, Forecasting, Parker Hannifin, Risk, Husqvarna Group, IDC, Big Lots, Organization, Technology, IBP, Artificial intelligence, Face, SEC, View, NASDAQ, Sarbanes, Sarbanes–Oxley Act, Solution, U.S. Securities and Exchange Commission, Telecommunication, Company, Form 10-K, ICT, Digital supply chain, Red, Renewable energy, Retail, Risk management, American Software Testing Qualifications Board

Logility, Inc., a leader in supply chain innovation powering the sustainable and resilient enterprise, has been positioned as a Leader in four IDC MarketScape reports for supply chain planning IDC MarketScape: Worldwide Holistic Supply Chain Planning 2022 Vendor Assessment (doc #US49578717, September 2022); IDC MarketScape: Worldwide Supply Chain Demand Planning 2022 Vendor Assessment (doc #US47619722, September 2022); IDC MarketScape: Worldwide Supply Chain Sales and Operations Planning 2022 Vendor Assessment (doc #US49568417, September 2022); and the IDC MarketScape: Worldwide Supply Chain Inventory Optimization 2022 Vendor Assessment (doc #US49568517, September 2022).

Key Points: 
  • Logility, Inc., a leader in supply chain innovation powering the sustainable and resilient enterprise, has been positioned as a Leader in four IDC MarketScape reports for supply chain planning IDC MarketScape: Worldwide Holistic Supply Chain Planning 2022 Vendor Assessment (doc #US49578717, September 2022); IDC MarketScape: Worldwide Supply Chain Demand Planning 2022 Vendor Assessment (doc #US47619722, September 2022); IDC MarketScape: Worldwide Supply Chain Sales and Operations Planning 2022 Vendor Assessment (doc #US49568417, September 2022); and the IDC MarketScape: Worldwide Supply Chain Inventory Optimization 2022 Vendor Assessment (doc #US49568517, September 2022).
  • The organization was also named as a Major Player in the IDC MarketScape: Worldwide Supply Chain Supply Planning 2022 Vendor Assessment (doc #US47620822, September 2022).
  • This recognition from the IDC MarketScape further highlights our ability to deliver valuable solutions that help our clients better manage their supply chains.
  • Accelerating the digital sustainable supply chain, Logility helps companies seize new opportunities, sense and respond to changing market dynamics and more profitably manage their complex global businesses.

Sypris Wins Award for Cryptographic Program

Retrieved on: 
Thursday, November 10, 2022
Online Privacy, Technology, Military, Semiconductor, Engineering, Security, Government Technology, Other Technology, Other Defense, Aerospace, Telecommunications, Contracts, Manufacturing, Networks, Defense, Mobile, Wireless, Hardware, Forward-looking statement, Terrorism, Natural gas, Patent, ACES, Partnership, Defense, Hand, Electronics, Invention, Efficiency, SEC, Failure, Form, Deep sea community, DOD, AKMS, Injury, US Military Communications-Electronics Board, Public policy, Compliance, Contract, Company, Government, Form 10-K, Program, General manager, LCMS, Engineering, Base erosion and profit shifting (OECD project), Electronic Key Management System, Disaster, COVID-19, LLC, Cryptocurrency, Risk management

Sypris Electronics, LLC, a subsidiary of Sypris Solutions, Inc. (Nasdaq/GM: SYPR), announced today that it has recently received a follow-on award from a U.S. DOD prime contractor to manufacture and test embedded circuit card assemblies that will perform certain of the cryptographic functions for the Army Key Management System (AKMS).

Key Points: 
  • Sypris Electronics, LLC, a subsidiary of Sypris Solutions, Inc. (Nasdaq/GM: SYPR), announced today that it has recently received a follow-on award from a U.S. DOD prime contractor to manufacture and test embedded circuit card assemblies that will perform certain of the cryptographic functions for the Army Key Management System (AKMS).
  • The embedded circuit card assemblies to be produced by Sypris will perform the cryptographic functions for a ruggedized, portable, hand-held simple key load device that will be used to securely receive, store and transfer data between compatible cryptographic and communications equipment.
  • We are pleased to extend our long-term partnership on and support of this important secure communications program, said Mark R. Kane, Vice President & General Manager of Sypris Electronics.
  • Sypris Electronics is a trusted provider of engineering and manufacturing services for complex, mission-critical electronic solutions for customers in the Defense, Space, Deep Sea Communications and Industrial markets.

Empire Petroleum Announces Timing of Third Quarter 2022 Earnings Release and Conference Call

Retrieved on: 
Thursday, November 10, 2022
Oil, Gas, Energy, Review, Forward-looking statement, NYSE, Petroleum, Toll, Securities Act of 1933, SEC, International, Securities Exchange Act of 1934, Company, Form 10-K, Security (finance)

Empire Petroleum (NYSE American: EP) (Empire or the Company), today announced that it will release its financial and operational results for the third quarter of 2022 after the market closes on Monday, November 14, 2022.

Key Points: 
  • Empire Petroleum (NYSE American: EP) (Empire or the Company), today announced that it will release its financial and operational results for the third quarter of 2022 after the market closes on Monday, November 14, 2022.
  • An investor conference call to review its results will be held on Tuesday, November 15, 2022, at 12:00 p.m. Eastern (11:00 a.m. Central).
  • The call will be hosted by Tommy Pritchard, the Companys Chief Executive Officer, and Mike Morrisett, Empires President.
  • Details for the conference call are as follows:
    Telephone: 1-877-270-2148 (Toll free); 1-412-902-6510 (International); participants should ask to be joined into the Empire Petroleum Corporation call.